Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. advantage

ADVANTAGE SIGNED

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADVANTAGE project word cloud

Explore the words cloud of the ADVANTAGE project. It provides you a very rough idea of what is the project "ADVANTAGE" about.

ground    elusive    care    clinical    companies    proof    validated    yield    hold    jobs    million    reduce    commercial    400    standards    burden    eradicate    accounting    reader    point    meet    advantage    cell    samples    summary    active    profile    performance    packages    successfully    microfluidic    clear    biosensia    confirm    platform    instrument    tuberculosis    rapid    costly    analytes    efforts    stimulate    serum    supply    cartridge    biomarker    globally    creation    time    protein    1    bn    massive    company    mediated    global    plus    analytical    investment    uk    tb    deaths    transitioning    biomarkers    improvements    risks    breaking    laboratory    patient    demonstrated    diagnostics    commercialisation    reagents    human    poc    structured    diagnostic    eight    variety    successful    slow    regulatory    ing    healthcare    panel    proven    private    proteinlogic    disruptive    poorly    practises    validation    security    assay    selective    unmet    despite   

Project "ADVANTAGE" data sheet

The following table provides information about the project.

Coordinator		 PROTEINLOGIC LIMITED 

Organization address
address: SHAKESPEARE HOUSE 42 NEWMARKET ROAD
city: CAMBRIDGE CAMBRIDGESHIRE
postcode: CB5 8EP
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://www.proteinlogic.com
 Total cost 3˙893˙307 €
 EC max contribution 3˙583˙396 € (92%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2018-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTEINLOGIC LIMITED UK (CAMBRIDGE CAMBRIDGESHIRE) coordinator 2˙921˙750.00
2    BIOSENSIA LIMITED IE (DUBLIN) participant 661˙646.00

Map

+-
Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly.

The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB.

The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises. Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies.

In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally.

 Deliverables

List of deliverables.
Clone scale Websites, patent fillings, videos etc. 2019-05-30 13:18:55

Take a look to the deliverables list in detail:  detailed list of ADVANTAGE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADVANTAGE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADVANTAGE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

Read More  

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Read More  

ADVANTAGE (2015)

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Read More